Pacira BioSciences, Inc.
- Last sale
- Nov 12, 2026 · +0.01%
- Market cap
- $1.46B
- 40.09M shares
- Filings
- 1,034
Q3 2026+3.6% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derived−23.5% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−42.7% FY25 yoy
- $1.46B
- 38.8×
- 2.0×
- 2.1×
- 11.56%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $726,411,000 | reported | |
| FY 2024 | 2024-12-31 | $700,966,000 | reported | |
| FY 2023 | 2023-12-31 | $674,978,000 | reported | |
| FY 2022 | 2022-12-31 | $666,823,000 | reported | |
| FY 2021 | 2021-12-31 | $541,533,000 revised | reported | |
| FY 2020 | 2020-12-31 | $429,647,000 revised | reported | |
| FY 2019 | 2019-12-31 | $418,926,000 | reported | |
| FY 2018 | 2018-12-31 | $332,427,000 | reported | |
| FY 2017 | 2017-12-31 | $284,342,000 revised | reported | |
| FY 2016 | 2016-12-31 | $270,073,000 revised | reported | |
| FY 2015 | 2015-12-31 | $248,997,000 | reported | |
| FY 2014 | 2014-12-31 | $197,668,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $148.33M | $148.33M | — | 40.49M sh | −12.5% | 108.5% |
| FY2024 | — | $25.00M | $25.00M | — | 46.28M sh | −0.5% | 14.0% |
| FY2023 | — | $0.00 | $0.00 | — | 46.50M sh | +1.2% | 0.0% |
| FY2022 | — | $0.00 | $0.00 | — | 45.95M sh | +2.5% | 0.0% |
| FY2010 | — | $2.00K | $2.00K | — | 574.03K sh | — | — |
Segments
Products
LineFY2025ShareChange
EXPAREL$575.13M79%+4.8%
ZILRETTA$116.63M16%−1.2%
iovera°$24.18M3.3%+6.0%
Bupivacaine liposome injectable suspension$6.91M1.0%−5.6%
Royalty revenue$3.56M0.5%−5.9%
Collaborative licensing and milestone revenue———
iovera°———
Total$726.41M
Pharmaceutical preparations
Pacira BioSciences, Inc. is the 44th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
TLXTelix Pharmaceuticals Ltd$803.8M55.6%0.9%—COLLCollegium Pharmaceutical, Inc$780.6M23.6%8.1%$776.1MCORTCorcept Therapeutics Inc$761.4M12.8%13.1%$8.1BEBSEmergent BioSolutions Inc.$742.9M28.8%7.1%$302.3M
PCRXPacira BioSciences, Inc. (this company)$726.4M3.6%1.0%$1.5B
AMPHAmphastar Pharmaceuticals, Inc.$719.9M1.7%13.6%$1.2BKNSAKiniksa Pharmaceuticals International, plc$677.6M60.1%8.7%$15.1BRAREUltragenyx Pharmaceutical Inc.$673.0M20.2%85.4%$1.6BAXSMAxsome Therapeutics, Inc.$638.5M65.5%28.7%$7.6BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Pacira BioSciences, Inc. · CIK 1396814 · Engraved from SEC EDGAR